Please find information below about the 2020 ASCO Annual Meeting. If you are a public relations professional looking for meeting information, please see our For PR Professionals page.

Key Dates

  • Embargoed Presscast for Credentialed Media: Wednesday, May 13
  • ASCO Proceedings I and Publish Only Abstracts Released: Wednesday, May 13, 2020 at 5:00pm ET

Apply For or Renew ASCO Media Credentials to Access Embargoed Materials

Visit ASCO's Media Headquarters to apply for media credentials, register to attend the meeting, access embargoed meeting information, and locate presscast dial-in information. For questions about how to navigate the site, please contact ASCO Media Registration.

  • Applying for or Renewing ASCO Media Credentials Instructions- Coming Soon
  • Frequently Asked Questions - Coming soon
  • Media Policies and Eligibility Information - Coming soon

Meeting Information

2019 Press Releases

Monday "News of the Day" Press Briefing: 

  • Use of Broader Criteria for Clinical Trial Enrollment Would Double Number of Eligible Patients With Lung Cancer
    CHICAGO - A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria, as proposed by ASCO and Friends of Cancer Research in 2017, would nearly double the percentage of patients eligible to enroll in clinical trials – from 52.3% to 98.5%. Read the full release

  • Colorectal Cancer Patients With Liver Metastases Live Just as Long After Laparoscopic Surgery as Open Surgery
    CHICAGO - The randomized OSLO-COMET trial found that laparoscopic surgery did not change chances of survival, when compared to open surgery, to remove metastases that had spread to the liver in patients with colorectal cancer. Read the full release.

  • Novel Targeted-Antibody Treatment Produced Responses in Nearly Half of Patients With Advanced Urothelial Cancer
    CHICAGO - A single arm, phase II clinical trial of 125 patients showed treatment with enfortumab vedotin (EV) – a new agent targeting Nectin-4, a protein found in 97% of urothelial cancers – produced responses in 44% of patients with locally advanced or metastatic forms of urothelial cancer. Read the full release.

  • Over 60 Percent of Gynecologic Oncologists Say They Have Experienced Sexual Harassment
    CHICAGO - A recent survey of U.S.-based physician members of the Society of Gynecologic Oncology found that 64% of respondents experienced sexual harassment in training or practice; among women, the rate was 71% and among men it was 51%. Read the full release.

Sunday "News of the Day" Press Briefing: 

  • Earlier Ovarian Cancer Diagnoses and Treatment Seen After ACA Implementation
    CHICAGO - An analysis of data from the National Cancer Database found that after implementation of the 2010 Affordable Care Act (ACA), ovarian cancer was diagnosed and treated at an earlier stage among women under age 65. More women also received treatment within 30 days of diagnosis, thereby increasing chances of survival. Read the full release

  • Private Insurance, Higher Regional Incomes, and Certain Practice Settings Predict Longer Survival for People With Multiple Myeloma
    CHICAGO - A new study analyzing demographic statistics from the National Cancer Database identified multiple socio-economic factors, including private insurance, living in a regionally higher-income area, and receiving treatment in certain practice settings as being associated with longer survival for patients with multiple myeloma. Read the full release

  • Racial Disparities in Access to Timely Cancer Treatment Nearly Eliminated in States With Medicaid Expansion
    CHICAGO - Previous racial disparities in timely cancer treatment between African American and white patients practically disappeared in states where Medicaid access was expanded under the Affordable Care Act (ACA), according to a new analysis of electronic health records of over 30,000 patients. Read the full release

  • Adding Enzalutamide to Standard First-Line Treatment Improves Survival for Men With Metastatic Hormone-Sensitive Prostate Cancer
    CHICAGO - An interim analysis of the international randomized, phase III ENZAMET trial found that 80% of men with metastatic hormone-sensitive prostate cancer (mHSPC) who received the non-steroidal anti-androgen (NSAA) medicine enzalutamide (Xtandi) along with the standard of care treatment were alive after 3 years compared with 72% of men who received other NSAAs along with standard treatment. Read the full release

  • Maintenance Therapy With PARP Inhibitor Olaparib Delays Progression of BRCA-Related Pancreatic Cancer
    CHICAGO - The randomized, phase III POLO trial found that maintenance therapy with the PARP inhibitor olaparib (Lynparza) significantly delayed the progression of metastatic pancreatic cancer in patients with BRCA gene mutations compared with placebo (median progression-free survival: 7.4 months vs. 3.8 months, respectively). Read the full release

Saturday "News of the Day" Press Briefing: 

  • Adding Ribociclib to First-Line Endocrine Therapy Significantly Improves Survival for Pre-Menopausal Women With Advanced Breast Cancer
    CHICAGO - ​The international, randomized phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone. Read the full release.

  • Front-Line Pembrolizumab Is Promising Alternative to Chemotherapy for Advanced Gastroesophageal Junction and Gastric Cancers
    CHICAGO - The KEYNOTE-062 phase III randomized clinical trial achieved its primary endpoint, showing that for patients with PD-L1-positive, HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) cancer, initial therapy with pembrolizumab (Keytruda) resulted in comparable (non-inferior) overall survival as standard chemotherapy. Read the full release.

  • Pembrolizumab Increases Historic Survival Rate for Certain People with Advanced Non-Small Cell Lung Cancer
    CHICAGO - Five-year data from the phase Ib KEYNOTE-001 clinical trial show that pembrolizumab (Keytruda) was safe and effective and substantially increased overall survival for advanced non-small cell lung cancer (aNSCLC). Read the full release.

May 15 Presscast:

  • Balanced, Low-Fat Diet Reduces Risk of Death From Breast Cancer in Postmenopausal Women
    ALEXANDRIA, Va. – The federally funded Women’s Health Initiative (WHI) clinical trial of dietary modification in nearly 49,000 postmenopausal women with no previous history of breast cancer reported that women who followed a balanced diet that was low in fat and included daily servings of fruits, vegetables, and grains had a 21% lower risk of death from breast cancer than women in the control group who continued their normal diet, which was higher in fat overall. Read the full release.
  • Pediatric MATCH Trial Finds More Frequent Targetable Genetic Alterations in Pediatric Cancers Than Predicted
    ALEXANDRIA, Va. – At the launch of the National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (NCI-COG Pediatric MATCH) trial in 2017, it was estimated that tumor sequencing in children, adolescents, and young adults with treatment-refractory cancers – cancers that do not respond to treatment– would identify genetic alterations that matched an investigational targeted therapy in 10% of study participants. Read the full release.
  • Entrectinib Produces Responses in Children and Adolescents With CNS and Other Cancers That Have Specific Gene Fusions
    ALEXANDRIA, Va. – In a phase I/IB study of 29 patients, age 4.9 months to 20 years, with rare central nervous system tumors, neuroblastoma, or other solid tumors, responses to entrectinib, a novel targeted treatment, were seen in 12 of the 28 evaluable patients. Read the full release.
  • Low-Dose Chemotherapy Regimen Effective in Older and Frail Patients With Gastroesophageal Cancer
    ALEXANDRIA, Va. – The phase III GO2 randomized trial of 514 older and frail people in the United Kingdom with advanced gastroesophageal cancer found that the lowest tested dose of oxaliplatin (Eloxatin) and capecitabine (Xeloda) was comparable to the highest dose in terms of delaying disease progression and minimizing side effects. Read the full release.
  • Lenalidomide Reduces Risk That Precancer Myeloma Will Progress to Overt Multiple Myeloma in High Risk Individuals
    ALEXANDRIA, Va. – The phase II/III E3A06 randomized clinical trial found that lenalidomide (Revlimid) significantly reduces the risk of smoldering multiple myeloma (SMM) -- a precancerous condition -- from progressing to cancer in patients at moderate or high-risk. Read the full release.

2019 Annual Meeting Press Briefing Recordings:

Media Resources

Questions About Obtaining ASCO Media Credentials?